Cantor Fitzgerald analyst Carter Gould initiated coverage of Vaxcyte (PCVX) with an Overweight rating.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Biotech Alert: Searches spiking for these stocks today
- Vaxcyte’s Promising Prospects: Buy Rating Reinforced by Positive Phase 2 Data and Strategic Expansion
- Optimistic Buy Rating for Vaxcyte Amid Vaccine Development Challenges and Strategic Adjustments
- BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’
- Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating